Intermediate- 2 Risk Myelofibrosis in a 68-Year-Old Woman

home / case-based-peer-perspectives / intermediate-2-risk-myelofibrosis-in-a-68-year-old-woman

Dr. Bose discusses the case of a 68-year-old woman with intermediate-risk myelofibrosis, including his initial impressions of the case, the key factors he considers when selecting initial therapy, and his perspective on the efficacy and safety of JAK inhibitors based on clinical trial data. He also covers timing of ruxolitinib initiation, managing anemia in patients on ruxolitinib, preserving quality of life, and the unmet needs and emerging therapies in the management of intermediate myelofibrosis.